What do we really know about antibiotic pharmacodynamics?

被引:75
作者
Gunderson, BW
Ross, GH
Ibrahim, KH
Rotschafer, JC
机构
[1] Univ Minnesota, Coll Pharm, Dept Expt & Clin Pharmacol, Minneapolis, MN 55455 USA
[2] Regions Hosp, Dept Clin Pharm, St Paul, MN USA
来源
PHARMACOTHERAPY | 2001年 / 21卷 / 11期
关键词
D O I
10.1592/phco.21.18.302S.33905
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Antibiotic pharmacodynamics is an evolving science that focuses on the relationship between drug concentration and pharmacologic effect, which is an antibiotic-induced bacterial death that also can manifest as an adverse drug reaction. The pharmacologic action of antibiotics usually can be described as concentration dependent or independent, although such classifications are highly reliant on the specific antibiotic and bacterial pathogen being studied. Quantitative pharmacodynamic parameters, such as ratio of the area under the concentration-time curve during a 24-hour dosing period to minimum inhibitory concentration (AUC(0-24):MIC), ratio of maximum serum antibiotic concentration to MIC (C(max):MIC), and duration of time that antibiotic concentrations exceed MIC (T > MIC), have been proposed as likely predictors of clinical and microbiologic success or failure for different pairings of antibiotic and bacteria. Thus far, most pharmacodynamic data reported have focused on fluoroquinolones, but work has been conducted on vancomycin, P-lactams, macrolides, aminoglycosides, and other antibiotics. Despite the development of a number of different pharmacodynamic modeling systems, remarkable agreement exists between in vitro, animal, and limited human data. Although still somewhat premature and requiring additional clinical validation, antibiotic pharmacodynamics will likely advance on four fronts: the science should prove to be extremely useful and represent a cost-effective and efficient method to help develop new antibiotics; formulary committees will likely use pharmacodynamic parameters to assist in differentiating antibiotics of the same chemical class in making antibiotic formulary selections; pharmacodynamic principles will likely be used to design optimal antibiotic strategies for patients with severe infections; and limited data to date suggest that the application of pharmacodynamic concepts may limit or prevent the development of antibiotic resistance. The study of antibiotic pharmacodynamics appears to hold great promise and will likely become a routine part of our daily clinical practices.
引用
收藏
页码:302S / 318S
页数:17
相关论文
共 100 条
[1]   ANALYSIS OF VANCOMYCIN TIME-KILL STUDIES WITH STAPHYLOCOCCUS SPECIES BY USING A CURVE STRIPPING PROGRAM TO DESCRIBE THE RELATIONSHIP BETWEEN CONCENTRATION AND PHARMACODYNAMIC RESPONSE [J].
ACKERMAN, BH ;
VANNIER, AM ;
EUDY, EB .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (08) :1766-1769
[2]   Pharmacodynamic analysis of the activity of quinupristin-dalfopristin against vancomycin-resistant Enterococcus faecium with differing MBCs via time-kill-curve and postantibiotic effect methods [J].
Aeschlimann, JR ;
Rybak, MJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (09) :2188-2192
[3]   Pharmacokinetics and pharmacodynamics of antibiotics in meningitis [J].
Andes, DR ;
Craig, WA .
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 1999, 13 (03) :595-+
[4]  
ANDES DR, 1999, 39 INT C ANT AG CHEM, P9
[5]  
ANDES DR, 1999, 39 INT C ANT AG CHEM, P8
[6]  
ANDES DR, 1999, 39 INT C ANT AG CHEM, P10
[7]   ADAPTIVE RESISTANCE FOLLOWING SINGLE DOSES OF GENTAMICIN IN A DYNAMIC INVITRO MODEL [J].
BARCLAY, ML ;
BEGG, EJ ;
CHAMBERS, ST .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (09) :1951-1957
[8]   COMPARISON OF GENTAMICIN DOSING REGIMENS USING AN INVITRO MODEL [J].
BEGG, EJ ;
PEDDIE, BA ;
CHAMBERS, ST ;
BOSWELL, DR .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1992, 29 (04) :427-433
[9]   COMPARATIVE-STUDY WITH ENOXACIN AND NETILMICIN IN A PHARMACODYNAMIC MODEL TO DETERMINE IMPORTANCE OF RATIO OF ANTIBIOTIC PEAK CONCENTRATION TO MIC FOR BACTERICIDAL ACTIVITY AND EMERGENCE OF RESISTANCE [J].
BLASER, J ;
STONE, BB ;
GRONER, MC ;
ZINNER, SH .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1987, 31 (07) :1054-1060
[10]   RANDOMIZED STUDY OF CARBENICILLIN PLUS CEFAMANDOLE OR TOBRAMYCIN IN THE TREATMENT OF FEBRILE EPISODES IN CANCER-PATIENTS [J].
BODEY, GP ;
KETCHEL, SJ ;
RODRIGUEZ, V .
AMERICAN JOURNAL OF MEDICINE, 1979, 67 (04) :608-616